早产儿(≤32周)母乳靶向强化与标准强化对生长发育影响的随机对照试验研究方案
本研究为随机对照试验,拟纳入胎龄≤32周的早产儿,在肠内喂养达80 ml/kg/day后随机接受标准强化(HMF, Nutricia)或靶向强化(模块化组分:蛋白质、碳水化合物、脂质),干预持续至矫正胎龄37周或出院。主要结局为至矫正胎龄36周或出院时的体重、身长和头围增长速度,次要结局包括12月龄和36月龄神经发育、出院时和4月龄体成分及坏死性小肠结肠炎等发病率。
要点
- 靶向强化根据母乳成分个体化补充模块化营养素,可能优于固定剂量的标准强化。
- 主要结局为体重、身长和头围的增长速度,随访至矫正胎龄36周或出院。
- 次要结局涵盖12月和36月龄神经发育、体成分及新生儿并发症发生率。
核心结论
- 靶向强化在新生儿重症监护环境中可行,若证实能改善生长和新生儿结局,可能成为极低出生体重儿的一线营养推荐。
研究设计与样本
- 随机对照试验,纳入胎龄≤32周、生后7天内的早产儿,肠内喂养达80 ml/kg/day后随机分组。
- 干预组接受标准强化(HMF, Nutricia)或靶向强化(模块化组分:Bebilon Bialka蛋白质、Polycal碳水化合物、Calogen脂质,均为Nutricia产品)。
- 干预持续至矫正胎龄37周或出院,父母和结局评估者设盲。
关键数值与推荐
- 主要结局为至矫正胎龄36周或出院时的体重、身长和头围增长速度。
- 次要结局包括12月龄Bayley Scale of Development III评估的神经发育(36月龄重复)、出院时和4月龄体成分、坏死性小肠结肠炎、脓毒症、早产儿视网膜病变和支气管肺发育不良的发生率。
临床怎么用
- 靶向强化可作为极低出生体重儿营养管理的潜在替代方案,但需待试验结果证实其改善生长和结局后再推荐为一线方案。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Human milk is recommended for all very low birth weight infants. Breastmilk is highly variable in nutrient content, failing to meet the nutritional demands of this group. Fortification of human milk is recommended to prevent extrauterine growth retardation and associated poor neurodevelopmental outcome. However, standard fortification with fixed dose multicomponent fortifier does not account for the variability in milk composition. Targeted fortification is a promising alternative and needs further investigation. METHODS: This randomized controlled trial will recruit preterm infants (≤ 32 weeks of gestation) within the first 7 days of life. After reaching 80 ml/kg/day of enteral feeding, patients will be randomized to receive standard fortification (HMF, Nutricia) or targeted fortification (modular components: Bebilon Bialka, Nutricia-protein; Polycal, Nutricia-carbohydrates; Calogen, Nutricia-lipids). The intervention will continue until 37 weeks of post-conception age or hospital discharge. Parents and outcome assessors will be blinded to the intervention. The primary outcome measure is velocity of weight, length, and head growth until 36 weeks post-conceptional age or discharge. Secondary outcomes include neurodevelopment at 12 months assessed with Bayley Scale of Development III, repeated at 36 months; body composition at discharge and at 4 months; and incidence of necrotizing enterocolitis, sepsis, retinopathy of prematurity, and bronchopulmonary dysplasia. DISCUSSION: Targeted fortification has previously been shown as doable in the neonatal intensive care unit context. If it shows to improve growth and neonatal outcome, choosing the targeted fortification as a first line nutritional approach in very low birth weight infants may become a recommendation. TRIAL REGISTRATION: ClinicalTrials.gov NCT03775785 , Registered on July 2019.
引用
- Seliga-Siwecka J, Chmielewska A, Jasińska K, et al. Effect of targeted vs standard fortification of breast milk on growth and development of preterm infants (≤ 32 weeks): study protocol for a randomized controlled trial. Trials. 2020. PMID: 33225961. doi:10.1186/s13063-020-04841-x
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。